title: [Clinical evaluation of ureteral stenting for managing extrinsic ureteral obstruction due to gynecological and gastrointestinal cancer].
abstract: We retrospectively reviewed patients who were treated with an indwelling ureteral stent to manage extrinsic ureteral obstruction due to advanced gynecological and gastrointestinal cancers. A total of 34 patients, including 17 with gynecological cancer and 17 with gastrointestinal cancer, underwent a successful initial ureteral stent placement from January 2007 to December 2011. Functional ureteral stent failures, which required percutaneous nephrostomy within 3 months after initial ureteral stenting, occurred in 14 of the 34 patients (41%) during follow-up. The risk factors of functional ureteral stent failure were bilateral ureteral obstruction, elevated serum creatinine level, poor performance status, subsequent therapy for primary cancer after ureteral stent placement, presence of peritonitis carcinomatosa, and gastrointestinal cancer. Patients with gastrointestinal cancer had a higher rate of stent failure than did those with gynecological cancer (p = 0.01). Median survival from the diagnosis of hydronephrosis for patients with gastrointestinal and gynecological cancers was 9 and 23 months, respectively (p = 0. 02). Retrograde ureteral stenting is a useful treatment for malignant ureteral obstruction. However, patients with gastrointestinal cancer had a high stent failure rate and a short survival time from the diagnosis of hydronephrosis. Indications for retrograde ureteral stenting for malignant ureteral obstruction should be carefully considered while taking into account stent failure risk, patient prognosis and quality of life.
authors.affiliation: The Department of Nephro-Urology, Nagasaki University Graduate School of Biomedical Sciences.
authors.forename: Kosuke
authors.initials: K
authors.lastname: Takehara
authors.affiliation: The Department of Nephro-Urology, Nagasaki University Graduate School of Biomedical Sciences.
authors.forename: Toru
authors.initials: T
authors.lastname: Onita
authors.affiliation: The Department of Nephro-Urology, Nagasaki University Graduate School of Biomedical Sciences.
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Mochizuki
authors.affiliation: The Department of Nephro-Urology, Nagasaki University Graduate School of Biomedical Sciences.
authors.forename: Yasuyoshi
authors.initials: Y
authors.lastname: Miyata
authors.affiliation: The Department of Nephro-Urology, Nagasaki University Graduate School of Biomedical Sciences.
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Igawa
authors.affiliation: The Department of Nephro-Urology, Nagasaki University Graduate School of Biomedical Sciences.
authors.forename: Hideki
authors.initials: H
authors.lastname: Sakai
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003401:Creatine / Q000097:blood; D004868:Equipment Failure / Q000706:statistics & numerical data; D005260:Female; D005500:Follow-Up Studies; D005770:Gastrointestinal Neoplasms / Q000150:complications* / Q000401:mortality; D005833:Genital Neoplasms, Female / Q000150:complications*; D006801:Humans; D006869:Hydronephrosis / Q000209:etiology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011788:Quality of Life; D012189:Retrospective Studies; D012307:Risk Factors; D015607:Stents; D015996:Survival Rate; D013997:Time Factors; D014517:Ureteral Obstruction / Q000209:etiology* / Q000628:therapy*
chemical_list: D003401:Creatine